Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et...
21 April, 2023
/
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that...
02 February, 2023
/
Montreal / July 4, 2022
NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation...
04 July, 2022
/
Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference.
The MedInvest Oncology Investor Conference will be hosted in...
23 June, 2022
/
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that...
30 January, 2022
/
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022
NexPlasmaGen will pitch its business opportunity to investors!
Montreal/December 24 – NexPlasmaGen, today announced that it is presenting...
24 December, 2021
/
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal...
03 November, 2021
/
NexPlasmaGen Inc. is pleased to announce that its patented cold plasma technology is in preparation for clinical investigation for the treatment of breast...
02 January, 2021
/
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program...
01 July, 2018
/